Eribulin exerts its pharmacologic effects by binding to the plus ends of microtubules and suppressing microtubule growth, without affecting microtubule shortening, and by inducing the formation of ...

The mice received different doses of TROP2-eribulin, a novel TROP2-targeting ADC, composed of an anti-TROP2 antibody and the eribulin payload, joined by a cleavable linker. The concentration and ...

1Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. *Corresponding Author: Daniel Skubleny, Department of Surgery, University of Alberta, 7813 96 Street ...

Trastuzumab deruxtecan (T-DXd) continued to show benefit in the updated data from the DESTINY-Breast03 trial (NCT03529110). Special attention should be paid to the toxicities of nausea and pneumonitis ...

By comparing eribulin-resistant breast cancer cell lines, we confirmed that BYL-719 could effectively overcome drug resistance. Summary/conclusion: The 3D cell culture is a novel and highly effective ...

Am J Health Syst Pharm. 2012;69(9):745-755. Patient demographic and baseline characteristics were comparable between the treatment groups. The median age was 55 years (range, 27–85 years).

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...